|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||694.40 - 709.20|
|52 Week Range||393.00 - 743.80|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||69.71|
|Earnings Date||Aug 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jul 03, 2019|
|1y Target Est||508.91|
Today, Eurofins Scientific, a world leader in Testing for Life, employing 50,000 people in 800 laboratories in 50 countries published its Q3 trading statement and on this occasion set new objectives for 2022: https://www.eurofins.com/media-centre/press-releases/2020-10-22/
Eurofins U.S. Clinical Diagnostics, announced that Clinical Enterprise Inc. has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for their at Home COVID-19 Nasal PCR Test. The EUA authorized self-collection kit gives consumers a minimally invasive, convenient and quick option to test from the comfort of their home. Results are provided via email within 24 hours of sample receipt.
While France has been experiencing a second wave of COVID-19 infections for several weeks now, technicians and clinical pathologists at Eurofins Biomnis have worked round the clock to increase capacity for RT-PCR, the reference test to detect SARS-CoV-2 since March. The laboratory has deployed two very high throughput automated platforms to meet rising testing demand.